New hope for tough blood cancers: early trial tests repurposed pill
NCT ID NCT05983965
Summary
This early-stage study is testing the safety and best dose of an oral medication called tazemetostat for adults with peripheral T-cell lymphoma that has returned or not responded to prior treatment. The drug is already approved for a different type of lymphoma. Researchers will enroll about 30 participants to monitor for side effects and determine a safe dose for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact
Contact
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.